Serina Therapeutics Announces Publication of SER-214 (POZ-Rotigotine) Article in Journal of Movement Disorders

Huntsville, AL, October 30th, 2013

Serina Therapeutics, Inc., a pharmaceutical research and development company that has developed a proprietary, patented polymer technology for drug development based on poly(oxazoline) - POZ, announced today that the company has published its first full article on the development of SER-214 in the Journal of Movement Disorders. The online version of the article entitled “Rotigotine Polyoxazoline Conjugate SER-214 Provides Robust and Sustained Anti-Parkinsonian Benefit” can be found on Serina’s website.

“We are pleased to announce the publication of our first full article detailing investigations with SER-214 in experimental animals with Parkinsonian behavior,” cited Randall Moreadith, MD, PhD, President and Chief Executive Officer of Serina Therapeutics, Inc. “The Journal of Movement Disorders is one of the premier journals in neurological science and it is an honor to have the article on SER-214, our lead pre-clinical candidate for treatment of Parkinson’s disease, appear in such a prestigious publication.” SER-214, a POZ polymer conjugate of the potent dopamine agonist rotigotine, demonstrated sustained anti-Parkinsonian benefit in experimental rats that had been rendered Parkinsonian by injection of 6-hydroxydopamine in a portion of the brain that would mimic dopaminergic neuron loss in humans. SER-214, which is being developed as a once-per-week injectable that fits in a standard insulin syringe, is currently in IND-enabling studies with plans to enter humans with Parkinson’s disease in the second half of 2014.

About Serina

Serina Therapeutics is a privately held pharmaceutical company located at the Hudson-Alpha Institute for Biotechnology in Huntsville, AL that develops novel polymer therapeutics based on its proprietary polyoxazoline (POZ) technology platforms. The founders and managers of Serina were formerly the key principals of Shearwater Polymers, a company that enabled twelve approved polyethylene glycol (PEG) products for various pharmaceutical partners. Besides developing its own pipeline of pharmaceutical products for Parkinson’s disease and cancer, Serina is also partnering its technology with pharmaceutical companies to develop high value products addressing unmet clinical needs.

For more information on Serina Therapeutics, please visit http://www.serinatherapeutics.com